Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Viking Therapeutics, Inc.NASDAQ: VKTX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $16.84M rose 16.8% year over year, ahead of the -11.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.5% from the prior quarter. Over 3 fiscal years it compounded at +44.2% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -1.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $16.84M+20.5% QoQ
- Last fiscal yearDec 2025
- $48.39M-1.8% YoY
- LTMJun 2026
- $50.71M-11.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.8% | -100.0% | -116.8 pp |
| 1 year | -1.8% | -100.0% | -98.2 pp |
| 3-year CAGR | +44.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 48.39M USD
- Year-over-year change
- -1.8%
- 4-year CAGR
- +45.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.39M | -1.8% |
| FY2024 | 2024-12-31 | 49.28M | +33.1% |
| FY2023 | 2023-12-31 | 37.02M | +129.6% |
| FY2022 | 2022-12-31 | 16.12M | +50.6% |
| FY2021 | 2021-12-31 | 10.7M | — |
Selling, General & Admin vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 selling, general & admin of $50.71M is the 4th highest of the 7 companies compared; the peer median is $54.15M.
- Its year-over-year change of -11.8% is the lowest of 6, against a peer median of +38.0%.
- Over three fiscal years its annual growth of +44.2% compares with a peer median of +73.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.01B | +64.1% | +156.7% | 78.4% | |
| LTM Jun 2026 | $102.22M | +6.5% | +76.0% | 1435.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $59.07M | +263.5% | +71.2% | — |
| LTM Jun 2026 | $50.71M | -11.8% | +44.2% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $49.23M | — | — | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M | +38.0% | — | 38.0% |
| LTM Mar 2026 | $15.87M | +18.9% | +7.0% | 43.1% | |
| Peer median (excluding VKTX) | $54.15M | +38.0% | +73.6% | 60.8% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 431K |
| Gross Profit | 0 | 0 | 0 | 0 | (431K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Selling, General & Admin | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M |
| Operating Expenses | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| EBITDA | (54.68M) | (68.52M) | (85.52M) | (109.52M) | (359.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (55.68M) | (70.36M) | (100.83M) | (150.92M) | (393.34M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 703K | 1.59M | 15.02M | 40.94M | 33.7M |
| Interest Expense | 18K | 59K | 88K | 94K | 0 |
| Other Income / Expenses | 692K | 1.49M | 14.93M | 40.96M | 33.7M |
| Income Before Tax | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| EPS (Diluted) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| Weighted Avg Shares | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
| Weighted Avg Shares (Diluted) | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.